In this July 11, 2026 YouTube monologue, Dr. Ashley Frazee explains the upcoming FDA advisory committee meeting (July 23‑24) that will evaluate four popular research peptides—BPC‑157, thymosin beta‑4 (TB‑500), KPV, and MOTS‑c—for specific therapeutic indications. She outlines the committee’s role in determining whether compounding pharmacies may legally produce these peptides, clarifies that the meeting is about evidence strength rather than proving efficacy, and reviews the biology, pre‑clinical/clinical data, and current off‑label uses for each peptide. Frazee details BPC‑157’s evaluation for ulcerative colitis, TB‑500’s for wound healing, KPV’s for wound healing and inflammatory conditions, and MOTS‑c’s for obesity and osteoporosis, summarizing key mechanisms (angiogenesis, actin regulation, NF‑κB inhibition, AMPK activation) and animal study results. She then discusses the potential outcomes: approval could legitimize pharmacy compounding and curb the gray market, while rejection would keep peptides in a legal gray zone, possibly fueling unregulated sales and telehealth prescriptions. Throughout, she balances scientific explanation with practical concerns for patients and clinicians, invites audience interaction, and promotes her peptide education course.
Chapters
On July 23rd and 24th, the FDA is hosting a special council to decide the legal fate of 7 of the most popular peptides. If you use or know about BPC-157, TB-500, together known as the Wolverine blend, or the more recently popular MOTS-c, and have noticed the power of these peptides, they might be more prescribable soon. And this poses a very important question. What will this do to the gray market for peptides? Or will it do anything at all? Because this meeting isn't deciding whether these peptides work. It's deciding whether the evidence for specific medical uses is strong enough for compounding pharmacies to legally compound them. So today I want to walk you through exactly what the committee is reviewing, at least on the first day, what the science actually says for each peptide, and what people use them for, and what this meeting could realistically mean Whether you get your peptides from a doctor or not. But this video isn't as much about politics as it is about the science and the safety of these peptides. Several popular peptides were put on the Category 2, or do not compound, list in 2023 due to safety concerns and lack of human data. And a lot of people think that's bull. But people who aren't afraid of that and actually use peptides are convinced that the safety profile is high, And that the droves of humans using these peptides, as long as they're from reputable sources, I hope, is enough human data for them. So let's look at the exact science the FDA committee will review, what they are evaluating these compounds for, and what this means for you and I. Now, just so you know who this committee is, it's a group of experts who provide the FDA recommendations on which substances can be used in compounding pharmacies like Empower Pharmacy or Olympia Pharmacy or your neighborhood compounder, not CVS or Walgreens. Now, the committee is going to weigh scientific data on each compound to determine whether the clinical evidence justifies recommending each compound for specifically nominated therapeutic indications or diseases or treatments. And importantly, after this, if a compound is approved, doctors will retain the right to practice medicine and use the compounds for those indications or however they see fit. So a doctor can still prescribe BPC-157 for a torn tendon or arthritis off-label, even if the FDA only reviews it for gut health. The list gives access to the ingredient. It's not a restriction on how the doctor thinks it could help your biology, which is a good thing. So let me just give you a rundown on these 4 incredible peptides that the committee is reviewing on July 23rd. And I mean it when I say incredible, and you have the right to believe me or not. The The most obvious peptide, the first one on the docket, is BPC-157. I will admit that I used to think very poorly of this compound until I did a deep dive on it, had about 1,000 comments from people watching me say this, thank you very much. And then I started to realize that there are certain circumstances in which I think this peptide makes more sense to use. And if you want a video on that, let me know in the comments. So the FDA is specifically going to review BPC-157 in its ability to treat or heal Ulcerative colitis. Ulcerative colitis is an autoimmune disease in which you get ulcers anywhere from your rectum through your colon. It's terrible. But please let me know if you or someone you know has ever actually used BPC-157 for this condition and if it was orally or injectable. I have personally never talked to anyone who has used it for that and had success with it. I have seen it used orally using a pill like this one to help with gastric reflux, gastritis, and other gut symptoms related to IBS. but not ulcerative colitis. And the science on this is that it's a peptide fragment of something that we make in our stomachs called a body protection compound. It is the 157th labeled peptide fragment of that compound that's very stable in the gut, and so that's why it can be taken orally. We believe it triggers angiogenesis, or new blood vessel formation, in order to aid in healing injured tissues. And it also triggers other cascades in the body to sensitize and light up an area to let the body know that healing needs Done here, like an SOS. And that's why people actually use this compound for soft tissue repair like strains, sprains, arthritis, and the gut symptoms that I just described. I have played with it shortly after surgeries and PRP injections, and I think that when you use it during an acute healing window, its potential to help is a lot bigger. And please remember, I am a doctor on YouTube and I'm a bit of a wild one, but I am not your doctor, so don't take Any of this as personal medical advice and go doing things on your own. Let's move on to the famous sidekick to BPC-157, thymosin beta-4, or TB-500. The FDA is reviewing this one specifically for wound healing. Basically, TB-500 regulates actin. It's a cell-building protein. It acts like a cellular construction foreman, telling cells to migrate directly to the site of an injury In order to rebuild tissue. So people also tend to use this for healing injuries, joint pains, strains and sprains, same as BPC-157. And when you know the science of it, the combination of the 2 is really hard to say not to do. Now, a lot of people will use this blend and call it the Wolverine blend and add KPV to it. They'll add GHK copper to it too, and that's what the CLO stack is. But GHK copper is gonna have its own time to shine. It's Just not in July. But KPV is also being evaluated on July 23rd for wound healing and inflammatory conditions, which surprised me because there's some great research on KPV in animals and inflammatory bowel disease, which ulcerative colitis is. So it's a little interesting how they're evaluating BPC-157 for ulcerative colitis and not KPV, but I can't tell you what's going on in the minds of the FDA. However, inflammatory conditions makes a lot of good sense because of how KPV works. It's a 3 amino acid peptide fragment of a hormone that you make called alpha MSH, and it is a potent anti-inflammatory that enters the cell nucleus to turn off what I like to call the master switch of inflammation, NF-kappaB. Steroids like prednisone actually do this too, but steroids are like dropping a nuclear bomb on the immune system, and KPV is more like turning down the thermostat on an overactive oven. So what people actually use it for is healing injuries and arthritis, things like mast cell activation syndrome or overdriven histamine responses or issues, and gut inflammation. So the FDA is reevaluating this peptide for the right things, in my personal humble opinion. Moving on to the peptide that's gaining a lot of popularity lately. MOTS-c. Now, the FDA is reviewing this magical peptide for obesity and osteoporosis. This peptide is fascinating. It lives in your body naturally, and you make more of it when you do hard things that you're supposed to do, like exercise, cold plunging, temporary fasting, things like that. It activates a pathway called AMPK, which tells your cells to increase the biogenesis, or the making of new mitochondria, your energy factories. It mobilizes fatty acids for use. It increases angiogenesis for healing, like we discussed before. It increases insulin sensitivity, and it increases muscular fiber endurance. It really is exercise in a vial, and that's kind of what most people actually use it for— metabolic improvements, an exercise mimetic, a pre-workout peptide, sometimes fat loss. They don't necessarily use it for obesity and osteoporosis, but after going through the science with you, I'm sure you can understand why it's being evaluated for obesity. And we do have an incredible rat study showing rats being fed high-fat diets and given MOTS-c and completely avoiding becoming obese. And also another group of rats given MOTS-c reversed their obesity. The osteoporosis science here is that when a female goes through menopause, she loses estrogen protection over her mitochondria. And when her mitochondria go down for the count, then she's prone to osteoporosis. And we have another rat study showing MOTS-c basically reversing that problem. So the science is there. Those are the 4 peptides being evaluated on July 23rd. So what happens next? Well, this meeting isn't just a regulatory formality. If these are voted down, then clean, third-party tested, compounding pharmacy-grade options Disappear, forcing people to continue buying peptides on the research-use-only gray market. But let's be really honest, the reason for doing this meeting and evaluation is to hopefully bring peptides back into compounding and to destabilize the gray market. And there's also talk of trying to destabilize mass telehealth prescriptions without proper oversight from medical practitioners. But the FDA can hold all the meetings they want. The horse has already kind of left the barn, kicked down the fence, and is Halfway across the country by now. See, right now, compounding these peptides for human use is in a very legal gray zone. But if you look around, there's a lot of pharmacies taking the risk anyway. And research peptide websites are still popping up like weeds. So are venture-backed telehealth startups who are sitting on the sidelines with their fingers on the trigger, just waiting for this July meeting to give them a green light to flood your algorithm. But again, the gray market isn't shrinking. It's exploding. And I think it's because when the medical system fails to give people answers for their chronic pain, their gut issues, their injuries, and things like that, people don't just give up and stay broken, do they? They look for tools. The Wild West of peptides is still happening and it's kind of ramping up, and I'm just not convinced this is going to fix it. What do you guys think? But stay tuned if you want to know how the vote goes on July 23rd and 24th. Make sure you're subscribed. And if you want me to make part 2 of this video to talk about the other 7 compounds being evaluated, let me know in the comments. I have a peptide course for doctors and other practitioners or coaches looking to get a really organized overview on the science and research on these peptides without getting bored, and I'll link that in the description as well. I'm Dr. Ashley Frazee. I'm just a doctor with a passion for things that work, and I hope you have the best day.
